Table 2.
Efficacy outcomes in the poor genotype group*
| Outcome | Triflusal (n=240) |
Clopidogrel (n=244) |
Hazard ratio (95% CI) | P | ||
|---|---|---|---|---|---|---|
| n | Rate (%/yr) | n | Rate (%/yr) | |||
| All strokes (ischemic and hemorrhagic) | 16 | 2.9 | 14 | 2.2 | 1.23 (0.60–2.53) | 0.565 |
| Ischemic stroke | 14 | 2.5 | 11 | 1.7 | 1.37 (0.62–3.01) | 0.435 |
| Intracerebral hemorrhage | 2 | 0.4 | 3 | 0.5 | 0.74 (0.12–4.41) | 0.737 |
| Myocardial infarction or coronary revascularization | 1 | 0.2 | 2 | 0.3 | 0.56 (0.05–6.13) | 0.627 |
| Myocardial infarction | 1 | 0.2 | 1 | 0.16 | 1.11 (0.07–17.67) | 0.944 |
| Coronary revascularization | 0 | 0 | 1 | 0.16 | - | - |
| Major vascular events† | 17 | 3.0 | 15 | 2.4 | 1.23 (0.61–2.45) | 0.566 |
| All deaths | 3 | 0.5 | 3 | 0.5 | 1.11 (0.22–5.49) | 0.900 |
| Vascular causes | 0 | 0 | 0 | 0 | - | - |
| Nonvascular causes | 3 | 0.5 | 3 | 0.5 | 1.11 (0.22–5.49) | 0.900 |
CI, confidence interval.
*
A time-to-first-event model was used for each outcome category; rates are annualized. The total number of patient-years of exposure for the primary outcome measure (all strokes) was 559 for patients in the triflusal treatment group and 637 for those in the clopidogrel treatment group;
†
Major vascular events included stroke, myocardial infarction, and vascular death.